Janney Montgomery Scott
BCLI

Janney Montgomery Scott’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Janney Montgomery Scott’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,367
Closed -$5K – 2700
2024
Q3 		$5K Hold
1,367
– – ﹤0.01% 2645
2024
Q2 		$7K Hold
1,367
– – ﹤0.01% 2594
2024
Q1 		$12K Hold
1,367
– – ﹤0.01% 2703
2023
Q4 		$6K Buy
1,367
+34
+3% +$102 ﹤0.01% 2617
2023
Q3 		$4K Hold
1,333
– – ﹤0.01% 2550
2023
Q2 		$41K Buy
+1,333
New +$55.2K ﹤0.01% 2602
2023
Q1 		– Sell
-1,333
Closed -$33K – 2542
2022
Q4 		$33K Hold
1,333
– – ﹤0.01% 2526
2022
Q3 		$88K Buy
+1,333
New +$66.9K ﹤0.01% 2416
2021
Q1 		– Sell
-1,393
Closed -$95K – 2234
2020
Q4 		$95K Sell
1,393
-66
-5% -$8.99K ﹤0.01% 2184
2020
Q3 		$370K Buy
1,459
+733
+101% +$150K ﹤0.01% 1591
2020
Q2 		$122K Buy
726
+33
+5% +$3.56K ﹤0.01% 1913
2020
Q1 		$48K Buy
+693
New +$54.1K ﹤0.01% 1828

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Janney Montgomery Scott's BCLI Position: Q4 2024 in Review

Janney Montgomery Scott sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2024, closing a stake of 1,367 shares — an estimated $5K sold.

Janney Montgomery Scott first reported a position in BCLI in Q1 2020 and held it in 12 quarters. The position peaked at $370K in Q3 2020. 34 funds tracked by Wall St. Rank hold BCLI as of Q4 2024.

  • Janney Montgomery Scott reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2024 after selling out during the quarter.
  • Janney Montgomery Scott sold 1,367 BRAINSTORM CELL THERAPUTC shares in Q4 2024, an estimated $5K.
  • Janney Montgomery Scott first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2020 and held it in 12 quarters.
  • Janney Montgomery Scott's BRAINSTORM CELL THERAPUTC position peaked at $370K in Q3 2020.
  • 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2024.

Based on Janney Montgomery Scott's 13F filing for Q4 2024, filed 17 Jan 2025.